The Market is Evolving—Fast.

In 2025, the European cannabis industry is undergoing one of its fastest transformations to date. Legal reforms, shifting consumer expectations, and a wave of novel cannabinoids are changing the landscape—demanding agility, knowledge, and responsibility from every serious player in the market.

At Solovya®, we believe leadership in this space comes not just from having products, but from understanding them—and from sharing that knowledge openly.

Key Shifts in the 2025 Cannabis Market

The most significant development? Germany’s legalization of adult-use cannabis—a landmark decision, though accompanied by strict regulatory controls. Meanwhile, medical cannabis and CBD innovation remain the fastest-growing and most stable sectors, with strong momentum across Germany, the UK, and Italy.

CBD itself is evolving. Customers are no longer simply looking for “CBD oil” but are seeking targeted wellness outcomes. This is driving interest in minor cannabinoids like:

• CBG – known for its potential in focus and mood support

• THCV – associated with appetite and energy regulation

• H4-CBD and CBDP – novel molecules showing promising properties

Above all, consumer expectations have matured. They now demand transparency, verified safety, and educational value—not just branding hype.

The Rise and Fall of HHC

HHC was a star in 2023–2024, offering a psychoactive alternative that was (temporarily) legal. But regulators across Germany, France, Czech Republic, and beyond acted quickly—banning HHC and its analogues to protect public health.

The result? Consumers didn’t disappear. They adapted.

Today’s cannabinoid users are looking for safer, cleaner, and legally secure alternatives—and they want brands they can trust.

Spotlight on 10-OH-HHC & 10-OH-HHCP

A new class of cannabinoids has entered the spotlight: 10-OH-HHC and 10-OH-HHCP.

• 10-OH-HHC offers a milder, smoother experience—often compared to Delta-8 THC

• 10-OH-HHCP delivers stronger relaxation effects, with a more stable and predictable profile

Both compounds currently exist in legal grey zones across much of Europe—not explicitly banned, but under active observation by regulators. That makes transparency and responsibility absolutely critical for anyone offering these products.

Solovya’s Approach: Education First, Always

We believe that the brands who will thrive long-term are those who educate first, sell second.

That’s why we provide:

✅ Clear communication on what each cannabinoid does
✅ Lab-tested transparency for every product
✅ Up-to-date compliance documentation
✅ Partner support through regulatory changes

We don’t hype trends. We build trust.

Looking Ahead: Navigating Change With Confidence

Yes, markets change. Regulations tighten. But one thing remains constant:

Trust builds lasting success.

At Solovya®, our mission is to be more than just a supplier. We are a knowledge partner—here to support your business with clarity, compliance, and commitment.

Whether you’re exploring CBD, CBG, or the emerging world of 10-OH cannabinoids:
We’re with you. Every step of the way.

Solovya® – Trusted Knowledge. Trusted Products.
Your partner in the future of cannabinoids.